Melissa Elder, M.D. PhD

 

 

Summary of Research Interest

Dr. Elder’s research program concentrates on clinical trials for pediatric patients with immunologic and rheumatologic disorders. She was the site principal investigator for a National Institutes of Health study focusing on the development of new treatments for children with juvenile arthritis, the results of which were published in the leading rheumatology journals.  She remains the principal investigator for studies focusing on immune protocols to improve tolerance to enzyme replacement for treatment of Pompe disease and she is the site co-principal investigator for one study in Duchenne muscular dystrophy.  She also received external grant support funding from Children’s Medical Services in the Department of Health to be the cardiac transplant immunologist and to direct the SCID Newborn Screening program at UF. In addition to Pediatrics, Dr. Elder is currently a member of the graduate faculty in the Departments of Pathology, Immunology, and Laboratory Medicine. Her primary long-term goal is to continue to participate in research and integrate insights learned from clinical/translational investigation into innovative treatment strategies that will improve outcomes of children with rheumatic diseases or immunodeficiencies.

 

Active and Past Contracts and Grants Awards

 Active

  • Canadian Institutes of Health, Research Emerging Team Grants: Rare Diseases, “Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes (Pediatric Vasculitis Initiative or PedVas),” M. Elder, site PI. 11/15/2013-present
  • AVI BioPharma 4658-US-202, “Open Label, Multiple-Dose Efficacy, Safety, and Tolerability Study of Eteplirsen in Patients with Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201,” B.Byrne MD, site PI, M. Elder, Investigator. 5/1//2012-present
  • Department of Health/Children’s Medical Services Comprehensive Cardiac Program; M. Elder, Transplant Immunologist. 12/1/2008-present
  • FL Dept of Health. Children’s Medical Services Genetics/Newborn/CF Screening Program (Site Director for SCID Newborn Screening). 10/1/2012-ongoing 

Past 

  • Shands Hospital, Medical Director, Pediatric Infusion Room. 9/1/2013-6/30/2015
  • Genzyme AGLU03606, “ADVANCE: “A Phase 4, Open-Label, Prospective Study in Patients with Pompe Disease to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale,” B. Byrne, MD, site PI; M. Elder, site Co-I. 5/1/2012-10/31/2013
  • NIH (NIAMS) NO1-AR-7-0015; “IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis, Randomized Double Blinded Placebo Controlled Multicenter Trial (RAPPORT),” N. Ilowite, MD, PI; M. Elder, site PI. 11/1/2011-12/31/2012
  • FL Dept of Health, “Children’s Medical Services Consolidated Rheumatology Program”. 7/1/2008-6/30/2009
  • Children’s Miracle Network, “AAV Gene Therapy for Severe Combined Immunodeficiency due to Adenosine Deaminase Deficiency,” M. Elder, PI.
  • NIH 3 R01 MH063914; “Prospective Study of PANDAS,” W. Goodman, MD, PI; M. Elder, Co-I. 7/15/2003-3/31/2007
  • Children’s Miracle Network, ““Recombinant AAV1-mediated Gene Transfer for Correction of Adenosine Deaminase Deficiency in Mice,” M. Elder, PI. 1/1/2005-12/31/2006
  • American Heart Association Grant-in-Aid; “Immunological and Neurodevelopmental Consequences of Chromosome 22q11.2 Deletion Syndrome;” M. Elder, PI. 1/1/2001-5/31/2003
  • NIH 1 R01 NR04835-01A1; “Fatigue, Pain, and Sleep Problems during Radiation,” C. Miaskowski, RN, PhD, PI; M. Elder., Co-I. 9/1/1999-4/30/2003
  • NIH 3 M01 RR01271; Pediatric Clinical Research Center; H. Debas, MD, PI; M. Elder, Associate Program Director. 12/2001-4/30/2003
  • NIH U01 AI41089; Pediatric AIDS Clinical Trials Group Immunology Core Laboratory; D. Wara, MD, PI; M. Elder, Co-I. 3/1/2001-4/30/2003
  • NIH 3 M01 RR01271; Pediatric Clinical Research Center; H. Debas, MD, PI; M. Elder, Core Laboratory Director. 7/1/1998-11/30/2001
  • Lucille Packard Foundation for Children’s Health, Stanford-UCSF Divisions of Pediatric Rheumatology Award. 10/1/1999-9/30/2001
  • NIH 1 P01 AI45865-01; “Human Immune Cell Maturation during Ontogeny and Infection;” F. Brodsky, DPhil, PI; M. Elder., Co-I; “Expression and Function of the Syk Kinase in Human and Murine T Cell Lineages.” 9/1/1999-9/1/2001
  • NIH AR20684; Multipurpose Arthritis and Musculoskeletal Disease Center; D. Wofsy, MD, PI; M. Elder, Co-I, Development and Feasibility Award; “Role of Syk in T-Cell Activation and Development of Autoimmunity.” 1/1/1999-12/31/2001
  • NIH U01 AI41089; Pediatric AIDS Clinical Trials Group Immunology Core Laboratory; D. Wara, MD, PI; M. Elder, Co-I. 3/1/1997-2/28/2001
  • NIH 3 M01 RR01271; Pediatric Clinical Research Center; H. Debas, MD, PI; M. Elder, Co-I, Clinical Associate Physician Award; “Signaling Kinases in Human T-Cell Development.” 7/1/1995-6/30/1998
  • UCSF Pre-Tenure Award; “Signaling Kinases in Human T-Cell Development;” M. Elder, PI. 9/1/1996-8/30/1997
  • NIH 3 M01 RR01271; Pediatric Clinical Research Center; H. Debas, MD, PI; M. Elder, Core Laboratory Director. 10/1/1993-6/30/1996
  • NIH 5 P30 HD28825; Child Health Research Center; L. Shapiro, MD, PI; M. Elder, Junior Investigator Award; “Severe Combined Immunodeficiency due to ZAP-70 Deficiency.” 8/1/1992-8/31/1995
  • Merck-American Federation for Clinical Research MD-PhD Postdoctoral Award; “Structure and Regulation of the Human Interferon-Gamma Promoter;” M. Eder, PI. 7/1/1991-12/31/1994

 

Publications

Peer-Reviewed

  • Modica RF, Lomax KG, Batzel P, Shapardanis L, Katzer KC, Elder ME. The Family Journey to Diagnosis with Systemic Juvenile Idiopathic Arthritis: a Cross-sectional Study of the Changing Social Media Presence. Open Access Rheumatol 8:61-71. 2016
  • Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, Twilt M, Benseler SM, Campillo S, Charuvanij S, Dancey P, Eberhard BA, Elder ME, Hersh A, Higgins G, Huber AM, Khubchandani R, Kim S, Klein-Gitelman M, Kostik M, Lawson E, Lee T, Lubieniecka JM, McCurdy D, Moorthy LN, Morishita KA, Nielsen SM, O’Neil KM, Reiff A, Ristic G, Robinson AB, Sarmiento A, Shenoi S, Toth MB, Van Mater H, Wagner-Weiner L, Weiss JE, White AJ, Yeung RS; ARChiVe Investigators Network within the PedVas initiative. Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA). An ARChiVe study. Arthritis Rheumatol 68(10):2514-2516. 2016
  • Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators*; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group, de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P; International Childhood Arthritis Genetics (INCHARGE) Consortium; British Society of Pediatric and Adolescent Rheumatology BSPAR Study Group. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 29;112(52):15970-15975. (*contributor/member) 2015
  • Autmizguine J, Cohen-Wolkowiez M, Ilowite N; RAPPORT Investigators*. Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol 55:39-44. (*contributor/member) 2015
  • Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is protective against Anti-AAV capsid immune response: A Human Subject Case Study. Mol Ther Methods Clin Dev 1. pii: 14033. 2014
  • Ilowite N, Prather K, Lokhnygina Y, Schanberg L, Elder M, Milojevic D, Verbsky J, Spalding S, Kimura Y, Imundo L, Punaro M, Sherry D, Tarvin S, Zemel L, Birmingham J, Gottlieb B, Miller M, O’Neil K, Ruth N, Wallace C, Singer N, Sandborg C. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis (RAPPORT), Arthritis Rheumatol 66:2570-2079. 2014
  • Rouster-Stevens KA, Ardoin SP, Cooper AM, Becker ML, Dragone LL, Huttenlocher A, Jones KB, Kolba KS, Moorthy LN, Nigrovic PA, Stinson JN, Ferguson PJ; American College of Rheumatology Pediatric Rheumatology Core Membership Group*. Choosing Wisely: the American College of Rheumatology’s Top 5 for pediatric rheumatology. Arthritis Care Res 66:649. (*member) 2014
  • Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG for the Childhood Myositis Heterogeneity Collaborative Study Group*. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res 66:732. (*contributor/member) 2014
  • Elder ME, Nayak S,p Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 183(3):847-854. 2013
  • Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, with the Childhood Myositis Heterogeneity Collaborative Study Group.* The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92:223-243. (*contributor/member) 2013
  • Shah M, Targoff IN, Rice MM, Miller FW, Rider LG with the Childhood Myositis Heterogenity Collaborative Study Group*. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum 65:1934-1941. (*member) 2013
  • Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice M, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group.* The clinical subgroup phenotypes of the juvenile idiopathic inflammatory myopathies, Medicine (Baltimore) 92:25-41, 2013. (*member) 2012
  • Hedna VS,Patel A, Bidari S, Elder M, Hoh BL, Yachnis A, Waters MF. Takaysu’s arteritis: Is it a reversible disease? Case report and literature review. Surg Neurol Int 3:132. 2012
  • Vijayan V, Moran R, Elder ME, Sukumaran S. Acute onset opioid Induced hyperalgesia in a child with juvenile idiopathic arthritis, J Clin Rheumatol 18:349-351. 2012
  • Badugu S, Elder M, Smith T. Macrophage activation syndrome, an important differential diagnosis for septic shock. J Pediatric Intensive Care 1:211-216, 2012.
  • Silver JN, Elder M*, Conlon T, Cruz , Wright AJ, Srivastava A, Flotte TR. Recombinant AAV-mediated gene transfer for the potential therapy of adenosine deaminase deficient severe combined immune deficiency. Hum Gene Ther 22:935-949. (*thesis co-chair) 2011
  • Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA),* the Pediatric Rheumatology Collaborative Study Group (PRSCG), and the Paediatric Rheumatology International Trials Organisation (PRINTO). American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 63:929. (*member) 2011
  • Mamyrova G, O’Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.* Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 58:3941-50. (*member) 2008
  • Tokuyasu, TA, Cotter PD, Segraves R, Harris J, Elder ME, Gonzales M, Pinkel D, Albertson DG, Rauen KA.  Detection of single clone deletions using array CGH: Identification of submicroscopic deletions in the 22q11.2 deletion syndrome as a model system. Am J Med Genet 143:925-932. 2007
  • von Scheven E, Elder ME. Association between b2-glycoprotein I gene polymorphisms, pediatric SLE and antiphospholipid antibodies. Lupus 14:440-444. 2005
  • Schmidt M, Carbonaro DA, Speckmann C, Wissler M, Bohnsack J, Elder M, Aronow BJ, Nolta JA, Kohn DB, von Kalle C. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med 9:463-468. 2003
  • Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, Sutter RW. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 188:1845-1852. 2003
  • Lu TT, Emery H, Elder ME, Wara D, von Scheven E. Thrombosis and pediatric Wegener’s granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum 49:862-865. 2003
  • Schmidt M, Carbonaro DA, Speckmann C, Wissler M, Bohnsack J, Elder M, Aronow BJ, Nolta JA, Kohn DB, von Kalle C. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med 9:463-468. 2003
  • von Scheven E, Glidden D, Elder ME. Antibodies against b2-glycoprotein I in pediatric patients with SLE or antiphospholipid antibody syndrome. Arthritis Rheum 47:414-420. 2002
  • Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, Bucher P, Pericak-Vance M, Haines JL, Weiss A, Hauser SL, Oksenberg JR. PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. Caucasian patients. Nat Genet 29:23-24. 2001
  • Chehimi J, Elder M, Greene J, Noroski L, Stiehm ER, Winkelstein JA, Sullivan KE. Cytokine and chemokine dysregulation in Hyper IgE syndrome. Clin Immunol 100:49-56. 2001
  • Rotbart HA, Webster AD for the Pleconaril Treatment Registry Group.* Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 32:228-235.  (*member) 2001
  • Elder ME, Skoda-Smith S, Kadlecek TA, Wang FL, Wu J, Weiss A. Distinct T-cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 166:656-661. 2001
  • Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M,  Shapira SK,  Farndon PA, Wara DW, Emmal SA, Ferguson BM. A novel x-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO)Am J Hum Genet 67:1555-1562. 2000
  • Seroogy CM, Wara DW, Bluth M, Dorenbaum A, White C, Durkin H, Elder ME. Cytokine profile of a long-term pediatric HIV survivor with Hyper-IgE syndrome and a normal CD4+ T-cell number. J Allergy Clin Immunol 104:1045-1051. 1999
  • Chu DH, van Oers NSC, Malissen M, Harris J, Elder M, Weiss A.. Pre-T cell receptor signals are responsible for the downregulation of Syk protein tyrosine kinase expression. J Immunol 163:2610-2620. 1999
  • Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burroto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Synder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 4:775-780. 1998
  • Elder M, Hope T, Parslow T, Umetsu D, Wara D, Cowan M. Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell Immunol 165:110-117. 1995
  • Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureiy A, Lawrence K, Wells S, Moen RC, Bastian J, Williams-Herman DE, Elder M, Wara D, Bowen T, Hershfield MS, Mullen CA, Blaese RM, Parkman R. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1:1017-1023. 1995
  • Chan AC, Kadlecek TA, Elder ME, Gray JW, Iwashima M, Filipovich AH, Parslow TG, Weiss A. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264:1599-1601.1994
  • Elder ME, Lin D, Clever J, Chan AC, Hope T, Weiss A, Parslow TG. Human severe combined immunodeficiency due to a defect in ZAP-70, a T-cell tyrosine kinase. Science 264:1596-1599. 1994
  • Benkerrou M, Wara D, Elder M, Dror Y, Merino A, Colombe B, Cowan M. B cell reconstitution after mismatched bone marrow transplant: in vitro anti-tetanus toxoid antibody production. J Clin Immunol 14:98-106. 1994
  • Hope TJ, Klein NP, Elder ME, Parslow TG. Trans-dominant inhibition of HIV-1 rev occurs through the formation of inactive protein complexes. J Virol 66:1849-1855. 1992
  • Winter WE, Robbins V, Elder M, Barret DJ, Martin N, Maclaren NK. Thymosin and the spontaneously diabetic BB rat.  Autoimmunity 1:115-23. 1988
  • Maclaren N, Elder M, Robbins V, Riley W. Autoimmune diathesis and T lymphocyte immunoincompetence in BB rats. Metabolism 32:92-96. 1983
  • Elder M. Maclaren N. Identification of profound T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J Immunol 130:1723-31. 1983
  • Elder M, Maclaren N, Riley W, McConnell T. Gastric parietal cell and other autoantibodies in the BB rat. Diabetes 31:313-18. 1982
  • Elder M, Maclaren NK, Riley WJ. Gonadal autoantibodies in patients with hypogonadism and/or Addison’s disease. J Clin Endocrinol Metabol 52:1137-42. 1981

Non-Peer Reviewed

  • Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, Smith BK, Fuller DD, Lawson LA, Mah CS. Pompe disease gene therapy. Hum Mol Genet 20:R61-8. 2011
  • Elder ME. T-cell immunodeficiencies. Pediatr Clin North Am 47:1253-1274. 2000
  • Elder ME. ZAP-70 and defects of T-cell receptor signaling. Semin Hematol 35:310-320. 1998
  • Elder ME. SCID due to ZAP-70 deficiency. J Pediatr Hematol Oncol 19:546-550. 1997
  • Elder ME. Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP-70. Pediatr Res 39:743-748. 1996

Books Edited

  • Elder, ME. (section editor). The Immune System. In Pediatrics & Perinatology: The Scientific Basis. PD Gluckman, MA Heymann (eds). Arnold Press, London, pp. 891-927. 1996

Chapters & Other Publications

  • Gupta N, Nguyen CQ, Modica RF, Elder ME, Garin EH. Pediatr Rheumatol Online J. 2017 Apr 11;15(1):21. doi: 10.1186/s12969-017-0156-2
  • Morishita KA, Moorthy LN, Lubieniecka JM, Twilt M, Yeung RSM, Toth MB, Shenoi S, Ristic G, Nielsen SM, Luqmani RA, Li SC, Lee T, Lawson EF, Kostik MM, Klein-Gitelman M, Huber AM, Hersh AO, Foell D, Elder ME, Eberhard BA, Dancey P, Charuvanij S, Benseler SM, Cabral DA; ARChiVe Investigators Network within the PedVas Initiative. Arthritis Rheumatol. 2017 Jul;69(7):1470-1479. doi: 10.1002/art.40112. Epub 2017 Jun 9
  • Modica RF, Lomax KG, Batzel P, Shapardanis L, Katzer KC, Elder ME. Open Access Rheumatol. 2016 May 26;8:61-71. eCollection 2016
  • Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, Twilt M, Benseler SM, Campillo S, Charuvanij S, Dancey P, Eberhard BA, Elder ME, Hersh A, Higgins GC, Huber AM, Khubchandani R, Kim S, Klein-Gitelman M, Kostik MM, Lawson EF, Lee T, Lubieniecka JM, McCurdy D, Moorthy LN, Morishita KA, Nielsen SM, O’Neil KM, Reiff A, Ristic G, Robinson AB, Sarmiento A, Shenoi S, Toth MB, Van Mater HA, Wagner-Weiner L, Weiss JE, White AJ, Yeung RS; ARChiVe Investigators Network within the PedVas Initiative. Arthritis Rheumatol. 2016 Oct;68(10):2514-26. doi: 10.1002/art.39729
  • Seroogy C, Elder M. Combined Immunodeficiencies, in Manual of Molecular and Clinical Laboratory Immunology, 8th edition.  B Detrick, RG Hamilton, JD Folds (eds). ASM Press, Washington, D.C., pp. 721-736. 2016
  • Taylor N, Elder ME. SCID due to Defects in T-Cell-Receptor-Associated Protein Tyrosine Kinases (ZAP-70 and Lck), in Primary Immunodeficiency Diseases: A Molecular and Genetic Approach, 3rd edition. HD Ochs, CIE Smith, J Puck (eds). Oxford University Press, New York, pp.231-240. 2014
  • Elder ME. Periodic Fever Syndromes, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. Familial Mediterranean Fever, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. Non-Bacterial Osteitis Syndromes, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. Hereditary Periodic Fever Syndromes, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. Hyper-IgD, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. TRAPS (Hyberian fever), in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. PFAPA, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. Muckle Wells Syndrome, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. NOMID/CINCA, in Clinical Decision Support: Pediatrics. J McMillan, D Barrett, D Jones, C Boney (eds). Decision Support in Medicine, LLC, Wilmington, DE. http://www.decisionsupportinmedicine.com 2013
  • Elder ME. ZAP-70 Deficiency, in UpToDate. BD Rose (ed). UpToDate, Wellesley, MA. http://www.uptodate.com (updated yearly) 2002-2011
  • Elder ME. Investigation of Signal Transduction Defects, in Manual of Molecular and Clinical Laboratory Immunology, 7th edition. B Detrick, RG Hamilton, JD Folds (eds). ASM Press, Washington, D.C., pp. 901-905. 2007
  • Elder ME. Severe Combined Immunodeficiency Due to Defects in T Cell Receptor-Associated Protein Tyrosine Kinases, in Primary Immunodeficiency Diseases: A Molecular and Genetic Approach, 2nd edition. HD Ochs, CIE Smith, J Puck (eds). Oxford University Press, New York, pp. 203-211. 2006
  • Elder ME. Investigation of Signal Transduction Defects, in Manual of Clinical Laboratory Immunology, 6th edition. R Rose, RG Hamilton, B. Detrick (eds). ASM Press, Washington, D.C., pp.826-829. 2002
  • Elder ME, Weiss A. SCID Resulting from Mutations in the Gene Encoding the Protein Tyrosine Kinase ZAP-70, in Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. HD Ochs, CIE Smith, J Puck (eds). Oxford University Press, New York, pp.146-154. 1998
  • Elder ME. Investigation of Signal Transduction Defects, in Manual of Clinical Laboratory Immunology, 5th edition. R Rose, Conway de Macario, JD Folds, HC Lane, RM Nakamura (eds). ASM Press, Washington, D.C., pp.829-834. 2002
  • Parslow TG, Elder ME. Pathobiology of Immunodeficiency Disorders, in Cellular and Molecular Pathogenesis. A Sirica (ed). Raven Press, New York, pp.199-217. 1995
  • Elder M, Golbus M, Cowan M. Ontogeny of Human T and B Cell Immunity, in Fetal Tissue Transplants In Medicine. RG Edwards (ed). Cambridge Press, Cambridge, pp.97-127. 1992
  • Elder M, Maclaren N. Steroid Hormone Cell Autoimmunity, in Autoimmune Endocrine Diseases. TF Davis (ed). John Wiley & Sons, New York, pp 181-92. 1983